Genentech, Dako Submit Applications to FDA for Herceptin in HER2-Positive Stomach Cancer | GenomeWeb

By Turna Ray

This article was posted May 27.

Genentech recently submitted a supplemental biologics license application with the US Food and Drug Administration for Herceptin (trastuzumab) in addition to chemotherapy as a treatment for HER2-positive stomach cancer, including cancer that affects the gastroesophageal junction.

If approved by the FDA, Herceptin stands to be the first personalized cancer treatment for stomach cancer patients who overexpress the HER2 protein.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.